Jerry Radich of the Fred Hutchinson Cancer Center, writing in the February 2026 edition of DIA’s Global Forum magazine, lays out a framework for taking cutting-edge cancer therapies – currently…
Patients and carers with lived experience of a disease have valuable insights to share with physicians and drug developers alike. This is especially true of rare diseases, defined in the…
China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one…
John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He…
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
African healthcare and pharma are moving from ambition to action. Regular PharmaBoardroom contributor Lenias Hwenda explains how, after years of over-dependence on global supply chains, fragmented regulation, and limited local…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Insilico Medicine’s partnership with Hengtai Biotech to co-develop an AI-discovered NLRP3 inhibitor for CNS disorders and Ellipses Pharma’s licensing…
ISPOR’s Rob Abbott traces AI’s evolution in healthcare from early expert systems to today’s machine learning and large language models, arguing that AI is now central to health economics and…
Bristol Myers Squibb (BMS), faced with patent expiries for its two largest historical revenue-generators, is racing to replace them. The US giant is re-entering the hot-again neuroscience space, as well…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include WuXi XDC’s acquisition of TOT Biopharm to expand ADC CDMO capabilities, Sino Biopharma’s entry into RNAi therapeutics with the…
See our Cookie Privacy Policy Here
